Adult Stem Cells Are Helping Scleroderma Patients PDF Print E-mail
Wednesday, 20 July 2011 22:37
Dr. Richard Burt and colleagues at Northwestern University have just published a new study in The Lancet that provides more evidence for the success of adult stem cell transplant in treating System Sclerosis (Scleroderma).

Ten patients were treated with their own adult stem cells, and all improved at or before 12 months after treatment, compared with zero of the nine patients that received cyclophosphamide, a chemotherapeutic agent considered the “standard of care” for this disease. None of the adult stem cell-treated patients had their disease worsen, while 8 of the 9 chemo-treated patients showed worsening, and eventually 7 of the chemo patients switched to the adult stem cell treatment.

The researchers note that the adult stem cell treatment improves skin and lung function in these patients for up to 2 years (the length of the current study) and is preferable to the current standard of care.

The new report is accompanied by a commentary by Farge and Gluckman that says the Burt et al. study provides “the best data to date for transplantation in Scleroderma”, and “Despite the small number of patients and short follow-up of ASSIST, the findings of this trial are important for patients with systemic sclerosis, the medical community, and policy makers.”

Dr. Burt is featured in a recently-released video discussing his ideas for use of adult stem cells to treat patients with autoimmune diseases. Burt and his team are using this technique to help treat patients suffering from some 23 different diseases, and the techniques he has developed are now being used in treatment centers around the globe.

Adult stem cells are helping patients now.

Source: Prentice, D. (2011), "Adult Stem Cells Helping Patients With Scleroderma Skin Disease"; Lifenews.com; original article can be viewed here.

 
More articles :

» Jefferson Researchers Identify Mechanism Behind Fibrotic Disorder

Scientists from the of Thomas Jefferson University are now several steps closer to understanding the mechanism behind a novel systemic fibrotic disorder that affects some patients with renal insufficiency who receive imaging contrast agents for...

» A System Out of Breath: How Hypoxia Possibly Contributes to the Pathogenesis of Systemic Sclerosis

T. W. van Hal, L. van Bon, and T. R. D. J. RadstakeReceived 20 May 2011; Revised 18 August 2011; Accepted 7 September 2011Systemic sclerosis (SSc) is typified by vascular alterations and immunological disturbances and fibrosis of the skin and...

» Apoptosis Modulation as a Promising Target for Treatment of Systemic Sclerosis

St´ephane Chabaud and V´eronique J. MoulinReceived 1 June 2011; Revised 6 July 2011; Accepted 6 July 2011Systemic sclerosis (scleroderma, SSc) is a heterogeneous disease which develops into three forms: limited, intermediate, and diffuse. The...

» Small Intestinal Bacterial Overgrowth A Problem For Scleroderma Patients

More than a third of patients with systemic sclerosis and intestinal symptoms have an increase in gastrointestinal tract bacteria, an alteration in the type of gut microbes present, or both, based on data from a French study presented at the annual...

» Gastric Antral Vascular Ectasia in Systemic Sclerosis

Jill Johnson and Chris T. DerkReceived 9 June 2011; Accepted 26 August 2011Gastric antral vascular ectasia (GAVE) was first defined in 1984 by Jabbari et al. Its distinctive endoscopic appearance caused it to be also known as “watermelon...

» Cell Therapy Yields Promising Results For Scleroderma Treatment

Cytori Therapeutics, Inc. provided preliminary data from a study evaluating a potential treatment for Scleroderma based on the company's cell therapy. The investigator-funded, open-label, pilot study is being conducted on patients with Cutaneous...